^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INKmune (primed NK cell therapy)

i
Other names: primed NK cell therapy, PiNK, INB16
Associations
Trials
Company:
INmune Bio
Drug class:
NK cell stimulant
Related drugs:
Associations
Trials
4ms
Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy. (PubMed, J Immunother Cancer)
NK cell "memory" is a physiological state associated with resistance to MHC-mediated inhibition, increased metabolic function, mitochondrial fitness and avidity to NK-resistant target cells.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • CD69 (CD69 Molecule) • ICAM1 (Intercellular adhesion molecule 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
INKmune (primed NK cell therapy)
7ms
LAUREL: A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (clinicaltrials.gov)
P1, N=2, Terminated, Inmune Bio, Inc. | Trial completion date: Jan 2025 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Mar 2024; Slow/low Enrollment
Trial completion date • Trial termination • Trial primary completion date
|
INKmune (primed NK cell therapy)
10ms
Study of INKmune in Patients With mCRPC (CaRe Prostate) (clinicaltrials.gov)
P1/2, N=30, Recruiting, Inmune Bio, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
INKmune (primed NK cell therapy)
over1year
New P1 trial
|
INKmune (primed NK cell therapy)
2years
In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmuneTM (ASH 2022)
INKmune priming increased NK glycolysis and oxidative phosphorylation whilst enhancing mitochondrial respiratory capacity and maintaining glycolytic reserve...The TIML-NK have a distinct phenotypic, proteomic and metabolomic signature which mirrors the activity in vitro and in vivo. This is the first time memory-like NK cells have been generated in vivo without the need for cytokine induction or support and our findings inform the development of more optimal NK cell-based immunotherapeutic strategies for cancer.
Preclinical
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule)
|
INKmune (primed NK cell therapy)